Global Whole Genome Sequencing (WSG) Market By Procedures/Techniques (Large Whole-Genome Sequencing (>5Mb), Small Genome Sequencing (<=5Mb), Phased Sequencing, Human Whole-Genome Sequencing, De Novo); By Genome Type (Human, Plant, Animal, Microorganism, Virus, Others); By Application (Food Safety Management, Identification of genetic diseases, Drug Trials and Pharmacogenomics, Rare Diseases Diagnosis, Others); By End Use (Hospitals and Clinics, Academic Institutions and Research Institutions, Pharmaceutical and Biotechnology Companies, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
In terms of revenue, global whole genome sequencing (WSG) market was valued at US$ 5.20 Bn in 2021, growing at an estimated CAGR of 18.6% over the forecast period. The process of determining the completeness of the sequence of DNA of any organism’s genome at one time is known as whole genome sequencing. This process which is also termed as full genome sequencing or complete genome sequencing follows sequencing total chromosomal DNAs of any organism and also the one in mitochondria. In case of plants, sequencing is done by following the chloroplast. Whole genome sequencing has been in the picture since long but was only used as a tool for research. The clinics started using this technique post 2014 and since then the whole genome sequencing (WSG) market has only gone upwards in terms of growth.
Whole genome sequencing (WSG) market was immensely benefited by the coronavirus pandemic as genome sequencing gained massive popularity as it was used in clinical diagnostic tests and also to determine the impact of dreadful CoV-2 virus on the organisms.
Procedures/ Techniques Outlook
On the basis of procedures/ techniques, the whole genome sequencing (WSG) market has been divided into large whole-genome sequencing (>5Mb), small genome sequencing (<5Mb), phased sequencing, human whole-sequencing sequencing and De Novo sequencing. The large whole-genome sequencing (>5Mb) segment dominated in terms of market share in 2021. This process revolves around full sequencing of any organism’s genome and hence it is preferred the most by clinics.
Global Whole Genome Sequencing (WSG) Market Revenue & Forecast, (US$ Million), 2022 – 2030
Genome Type Outlook
On the basis of genome, the whole genome sequencing (WSG) market has been segregated into human, plant, animal, microorganism, virus and others. The human segment generates maximum revenue for this market. Humans are the most complete yet complicated organism and hence sequencing of its gene delivers answers to many questions and solutions to several prevalent problems. This is the reason why this segment mints majority of money for this market.
Application Outlook
On the basis of application, the whole genome sequencing (WSG) market has been bifurcated into food safety management, identification of genetic diseases, drug trials and pharmacogenomics, rare disease diagnosis and others. The drug trials and pharmacogenomics segment is witnessing rampant growth and the reason behind this is that there are several ailments which require urgent treatment and hence pharma companies are continuously conducting drug trials. Genome sequencing helps them understand how an organism will respond to the new drug. The demand for whole genome sequencing went drastically up recently as the coronavirus rattled the globe. The never seen before virus claimed lives of millions and genome sequencing helped determine the impact of it.
End User
The end user segment of the whole genome sequencing (WSG) market has been divided into hospitals and clinics, academic institutions and research institutions, pharmaceutical and biotechnology companies. The academic institutions and research institutions account for majority of revenue generated by this market. Research is a continuous process and since years, even before clinicians got introduced with whole genome sequencing, this process was being used as a research tool.
Region Outlook
North America accounted for a lion’s share of the revenue generated by the whole genome sequencing (WSG) market in 2021. The United States government led by President Joe Biden had announced a huge amount of $1 billion towards development of genomic sequencing and this is driving the growth of this market.
Competitive Landscape
The report provides both, qualitative and quantitative research of whole genome sequencing (WSG) market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Few of the major players operating in the whole genome sequencing (WSG) market are listed below:
- 10x Genomics
- Agilent Technologies
- BGI
- Eurofins Genomics, Inc.
- GENEWIZ
- Illumina, Inc.
- Macrogen Europe B.V
- Oxford Nanopore
- Qiagen N.V.
- Simplify Genomics
- Thermo Fisher Scientific, Inc.
- Veritas
- Other Market Participants
Global Whole Genome Sequencing (WSG) Market
By Procedures/ Techniques
- Large Whole Genome Sequencing (>5Mb)
- Small Genome Sequencing (<=5Mb)
- Phased Sequencing
- Human Whole Genome Sequencing
- De Novo Sequencing
By Genome Type
- Human
- Plant
- Animal Microorganism
- Virus
- Others
By Application
- Food Safety Management
- Identification
- Drug Trials and Pharmacogenomics
- Rare Disease Diagnosis
- Others
By End Use
- Hospitals
- Academic Institutions and Research Institutions
- Pharmaceutical and Biotechnology Companies
- Others
By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Forecast
Years: 2021 – 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Whole Genome Sequencing (WGS) Market
6. Market Synopsis: Whole
Genome Sequencing (WGS) Market
7. Whole Genome Sequencing (WGS) Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in
Whole Genome Sequencing (WGS) Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Whole Genome Sequencing (WGS) Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Whole Genome Sequencing (WGS) Market
8. Global Whole Genome Sequencing (WGS) Market Analysis and
Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global
Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
8.2. Global
Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
Procedures
8.2.1. Large
Whole-Genome Sequencing
8.2.1.1. Definition
8.2.1.2. Market Forecast, 2021 - 2029
8.2.1.3. Compound Annual Growth Rate (CAGR)
8.2.1.4. Regional Bifurcation
8.2.1.4.1. North America
8.2.1.4.1.1. Market
Forecast, 2021 - 2029
8.2.1.4.2. Europe
8.2.1.4.2.1. Market
Forecast, 2021 - 2029
8.2.1.4.3. Asia Pacific
8.2.1.4.3.1. Market
Forecast, 2021 - 2029
8.2.1.4.4. Middle East and Africa
8.2.1.4.4.1. Market
Forecast, 2021 - 2029
8.2.1.4.5. Latin America
8.2.1.4.5.1. Market
Forecast, 2021 - 2029
8.2.2. Small Genome Sequencing
8.2.2.1. Definition
8.2.2.2. Market Forecast, 2021 - 2029
8.2.2.3. Compound Annual Growth Rate (CAGR)
8.2.2.4. Regional Bifurcation
8.2.2.4.1. North America
8.2.2.4.1.1. Market
Forecast, 2021 - 2029
8.2.2.4.2. Europe
8.2.2.4.2.1. Market
Forecast, 2021 - 2029
8.2.2.4.3. Asia Pacific
8.2.2.4.3.1. Market
Forecast, 2021 - 2029
8.2.2.4.4. Middle East and Africa
8.2.2.4.4.1. Market
Forecast, 2021 - 2029
8.2.2.4.5. Latin America
8.2.2.4.5.1. Market
Forecast, 2021 - 2029
8.2.2.4.5.2.
8.2.3. Phased
Sequencing
8.2.3.1. Definition
8.2.3.2. Market Forecast, 2021 - 2029
8.2.3.3. Compound Annual Growth Rate (CAGR)
8.2.3.4. Regional Bifurcation
8.2.3.4.1. North America
8.2.3.4.1.1. Market
Forecast, 2021 - 2029
8.2.3.4.2. Europe
8.2.3.4.2.1. Market
Forecast, 2021 - 2029
8.2.3.4.3. Asia Pacific
8.2.3.4.3.1. Market
Forecast, 2021 - 2029
8.2.3.4.4. Middle East and Africa
8.2.3.4.4.1. Market
Forecast, 2021 - 2029
8.2.3.4.5. Latin America
8.2.3.4.5.1. Market
Forecast, 2021 - 2029
8.2.4. Human
Whole-Genome Sequencing
8.2.4.1. Definition
8.2.4.2. Market Forecast, 2021 - 2029
8.2.4.3. Compound Annual Growth Rate (CAGR)
8.2.4.4. Regional Bifurcation
8.2.4.4.1. North America
8.2.4.4.1.1. Market
Forecast, 2021 - 2029
8.2.4.4.2. Europe
8.2.4.4.2.1. Market
Forecast, 2021 - 2029
8.2.4.4.3. Asia Pacific
8.2.4.4.3.1. Market
Forecast, 2021 - 2029
8.2.4.4.4. Middle East and Africa
8.2.4.4.4.1. Market
Forecast, 2021 - 2029
8.2.4.4.5. Latin America
8.2.4.4.5.1. Market
Forecast, 2021 - 2029
8.2.5. De Novo
Sequencing
8.2.5.1. Definition
8.2.5.2. Market Forecast, 2021 - 2029
8.2.5.3. Compound Annual Growth Rate (CAGR)
8.2.5.4. Regional Bifurcation
8.2.5.4.1. North America
8.2.5.4.1.1. Market
Forecast, 2021 - 2029
8.2.5.4.2. Europe
8.2.5.4.2.1. Market
Forecast, 2021 - 2029
8.2.5.4.3. Asia Pacific
8.2.5.4.3.1. Market
Forecast, 2021 - 2029
8.2.5.4.4. Middle East and Africa
8.2.5.4.4.1. Market
Forecast, 2021 - 2029
8.2.5.4.5. Latin America
8.2.5.4.5.1. Market
Forecast, 2021 - 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By
Procedures
9. Global Whole Genome Sequencing (WGS) Market Analysis and
Forecasts, 2021 – 2029
9.1. Overview
9.2. Global
Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By Genome
Type
9.2.1. Human
9.2.1.1. Definition
9.2.1.2. Market Forecast, 2021 - 2029
9.2.1.3. Compound Annual Growth Rate (CAGR)
9.2.1.4. Regional Bifurcation
9.2.1.4.1. North America
9.2.1.4.1.1. Market
Forecast, 2021 - 2029
9.2.1.4.2. Europe
9.2.1.4.2.1. Market
Forecast, 2021 - 2029
9.2.1.4.3. Asia Pacific
9.2.1.4.3.1. Market
Forecast, 2021 - 2029
9.2.1.4.4. Middle East and Africa
9.2.1.4.4.1. Market
Forecast, 2021 - 2029
9.2.1.4.5. Latin America
9.2.1.4.5.1. Market
Forecast, 2021 - 2029
9.2.2. Plant
9.2.2.1. Definition
9.2.2.2. Market Forecast, 2021 - 2029
9.2.2.3. Compound Annual Growth Rate (CAGR)
9.2.2.4. Regional Bifurcation
9.2.2.4.1. North America
9.2.2.4.1.1. Market
Forecast, 2021 - 2029
9.2.2.4.2. Europe
9.2.2.4.2.1. Market
Forecast, 2021 - 2029
9.2.2.4.3. Asia Pacific
9.2.2.4.3.1. Market
Forecast, 2021 - 2029
9.2.2.4.4. Middle East and Africa
9.2.2.4.4.1. Market
Forecast, 2021 - 2029
9.2.2.4.5. Latin America
9.2.2.4.5.1. Market
Forecast, 2021 - 2029
9.2.3. Animal
9.2.3.1. Definition
9.2.3.2. Market Forecast, 2021 - 2029
9.2.3.3. Compound Annual Growth Rate (CAGR)
9.2.3.4. Regional Bifurcation
9.2.3.4.1. North America
9.2.3.4.1.1. Market
Forecast, 2021 - 2029
9.2.3.4.2. Europe
9.2.3.4.2.1. Market
Forecast, 2021 - 2029
9.2.3.4.3. Asia Pacific
9.2.3.4.3.1. Market
Forecast, 2021 - 2029
9.2.3.4.4. Middle East and Africa
9.2.3.4.4.1. Market
Forecast, 2021 - 2029
9.2.3.4.5. Latin America
9.2.3.4.5.1. Market
Forecast, 2021 - 2029
9.2.4. Microorganism
9.2.4.1. Definition
9.2.4.2. Market Forecast, 2021 - 2029
9.2.4.3. Compound Annual Growth Rate (CAGR)
9.2.4.4. Regional Bifurcation
9.2.4.4.1. North America
9.2.4.4.1.1. Market
Forecast, 2021 - 2029
9.2.4.4.2. Europe
9.2.4.4.2.1. Market
Forecast, 2021 - 2029
9.2.4.4.3. Asia Pacific
9.2.4.4.3.1. Market
Forecast, 2021 - 2029
9.2.4.4.4. Middle East and Africa
9.2.4.4.4.1. Market
Forecast, 2021 - 2029
9.2.4.4.5. Latin America
9.2.4.4.5.1. Market
Forecast, 2021 - 2029
9.2.5. Virus
9.2.5.1. Definition
9.2.5.2. Market Forecast, 2021 - 2029
9.2.5.3. Compound Annual Growth Rate (CAGR)
9.2.5.4. Regional Bifurcation
9.2.5.4.1. North America
9.2.5.4.1.1. Market
Forecast, 2021 - 2029
9.2.5.4.2. Europe
9.2.5.4.2.1. Market
Forecast, 2021 - 2029
9.2.5.4.3. Asia Pacific
9.2.5.4.3.1. Market
Forecast, 2021 - 2029
9.2.5.4.4. Middle East and Africa
9.2.5.4.4.1. Market
Forecast, 2021 - 2029
9.2.5.4.5. Latin America
9.2.5.4.5.1. Market
Forecast, 2021 - 2029
9.2.6. Others
9.2.6.1. Definition
9.2.6.2. Market Forecast, 2021 - 2029
9.2.6.3. Compound Annual Growth Rate (CAGR)
9.2.6.4. Regional Bifurcation
9.2.6.4.1. North America
9.2.6.4.1.1. Market
Forecast, 2021 - 2029
9.2.6.4.2. Europe
9.2.6.4.2.1. Market
Forecast, 2021 - 2029
9.2.6.4.3. Asia Pacific
9.2.6.4.3.1. Market
Forecast, 2021 - 2029
9.2.6.4.4. Middle East and Africa
9.2.6.4.4.1. Market
Forecast, 2021 - 2029
9.2.6.4.5. Latin America
9.2.6.4.5.1. Market
Forecast, 2021 - 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By
Genome Type
10. Global Whole Genome Sequencing (WGS) Market Analysis and
Forecasts, 2021 – 2029
10.1. Overview
10.2. Global
Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
Application
10.2.1. Food
Safety Management
10.2.1.1. Definition
10.2.1.2. Market Forecast, 2021 - 2029
10.2.1.3. Compound Annual Growth Rate (CAGR)
10.2.1.4. Regional Bifurcation
10.2.1.4.1. North America
10.2.1.4.1.1.
Market Forecast, 2021 - 2029
10.2.1.4.2. Europe
10.2.1.4.2.1.
Market Forecast, 2021 - 2029
10.2.1.4.3. Asia Pacific
10.2.1.4.3.1.
Market Forecast, 2021 - 2029
10.2.1.4.4. Middle East and Africa
10.2.1.4.4.1.
Market Forecast, 2021 - 2029
10.2.1.4.5. Latin America
10.2.1.4.5.1.
Market Forecast, 2021 - 2029
10.2.2. Identification
of genetic diseases
10.2.2.1. Definition
10.2.2.2. Market Forecast, 2021 - 2029
10.2.2.3. Compound Annual Growth Rate (CAGR)
10.2.2.4. Regional Bifurcation
10.2.2.4.1. North America
10.2.2.4.1.1.
Market Forecast, 2021 - 2029
10.2.2.4.2. Europe
10.2.2.4.2.1.
Market Forecast, 2021 - 2029
10.2.2.4.3. Asia Pacific
10.2.2.4.3.1.
Market Forecast, 2021 - 2029
10.2.2.4.4. Middle East and Africa
10.2.2.4.4.1.
Market Forecast, 2021 - 2029
10.2.2.4.5. Latin America
10.2.2.4.5.1.
Market Forecast, 2021 - 2029
10.2.3. Drug
Trials and Pharmacogenomics
10.2.3.1. Definition
10.2.3.2. Market Forecast, 2021 - 2029
10.2.3.3. Compound Annual Growth Rate (CAGR)
10.2.3.4. Regional Bifurcation
10.2.3.4.1. North America
10.2.3.4.1.1.
Market Forecast, 2021 - 2029
10.2.3.4.2. Europe
10.2.3.4.2.1.
Market Forecast, 2021 - 2029
10.2.3.4.3. Asia Pacific
10.2.3.4.3.1.
Market Forecast, 2021 - 2029
10.2.3.4.4. Middle East and Africa
10.2.3.4.4.1.
Market Forecast, 2021 - 2029
10.2.3.4.5. Latin America
10.2.3.4.5.1.
Market Forecast, 2021 - 2029
10.2.4. Rare Disease Diagnosis
10.2.4.1. Definition
10.2.4.2. Market Forecast, 2021 - 2029
10.2.4.3. Compound Annual Growth Rate (CAGR)
10.2.4.4. Regional Bifurcation
10.2.4.4.1. North America
10.2.4.4.1.1.
Market Forecast, 2021 - 2029
10.2.4.4.2. Europe
10.2.4.4.2.1.
Market Forecast, 2021 - 2029
10.2.4.4.3. Asia Pacific
10.2.4.4.3.1.
Market Forecast, 2021 - 2029
10.2.4.4.4. Middle East and Africa
10.2.4.4.4.1.
Market Forecast, 2021 - 2029
10.2.4.4.5. Latin America
10.2.4.4.5.1.
Market Forecast, 2021 - 2029
10.2.5. Others
10.2.5.1. Definition
10.2.5.2. Market Forecast, 2021 - 2029
10.2.5.3. Compound Annual Growth Rate (CAGR)
10.2.5.4. Regional Bifurcation
10.2.5.4.1. North America
10.2.5.4.1.1.
Market Forecast, 2021 - 2029
10.2.5.4.2. Europe
10.2.5.4.2.1.
Market Forecast, 2021 - 2029
10.2.5.4.3. Asia Pacific
10.2.5.4.3.1.
Market Forecast, 2021 - 2029
10.2.5.4.4. Middle East and Africa
10.2.5.4.4.1.
Market Forecast, 2021 - 2029
10.2.5.4.5. Latin America
10.2.5.4.5.1.
Market Forecast, 2021 - 2029
10.3. Key
Segment for Channeling Investments
10.3.1. By
Application
11. Global Whole Genome Sequencing (WGS) Market Analysis and
Forecasts, 2021 – 2029
11.1. Overview
11.2. Global
Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By End Use
11.2.1. Hospitals
and Clinics
11.2.1.1. Definition
11.2.1.2. Market Forecast, 2021 - 2029
11.2.1.3. Compound Annual Growth Rate (CAGR)
11.2.1.4. Regional Bifurcation
11.2.1.4.1. North America
11.2.1.4.1.1.
Market Forecast, 2021 - 2029
11.2.1.4.2. Europe
11.2.1.4.2.1.
Market Forecast, 2021 - 2029
11.2.1.4.3. Asia Pacific
11.2.1.4.3.1.
Market Forecast, 2021 - 2029
11.2.1.4.4. Middle East and Africa
11.2.1.4.4.1.
Market Forecast, 2021 - 2029
11.2.1.4.5. Latin America
11.2.1.4.5.1.
Market Forecast, 2021 - 2029
11.2.2. Academic
Institutions and Research Institutions
11.2.2.1. Definition
11.2.2.2. Market Forecast, 2021 - 2029
11.2.2.3. Compound Annual Growth Rate (CAGR)
11.2.2.4. Regional Bifurcation
11.2.2.4.1. North America
11.2.2.4.1.1.
Market Forecast, 2021 - 2029
11.2.2.4.2. Europe
11.2.2.4.2.1.
Market Forecast, 2021 - 2029
11.2.2.4.3. Asia Pacific
11.2.2.4.3.1.
Market Forecast, 2021 - 2029
11.2.2.4.4. Middle East and Africa
11.2.2.4.4.1.
Market Forecast, 2021 - 2029
11.2.2.4.5. Latin America
11.2.2.4.5.1.
Market Forecast, 2021 - 2029
11.2.3. Pharmaceutical and Biotechnology Companies
11.2.3.1. Definition
11.2.3.2. Market Forecast, 2021 - 2029
11.2.3.3. Compound Annual Growth Rate (CAGR)
11.2.3.4. Regional Bifurcation
11.2.3.4.1. North America
11.2.3.4.1.1.
Market Forecast, 2021 - 2029
11.2.3.4.2. Europe
11.2.3.4.2.1.
Market Forecast, 2021 - 2029
11.2.3.4.3. Asia Pacific
11.2.3.4.3.1.
Market Forecast, 2021 - 2029
11.2.3.4.4. Middle East and Africa
11.2.3.4.4.1.
Market Forecast, 2021 - 2029
11.2.3.4.5. Latin America
11.2.3.4.5.1.
Market Forecast, 2021 - 2029
11.2.4. Others
11.2.4.1. Definition
11.2.4.2. Market Forecast, 2021 - 2029
11.2.4.3. Compound Annual Growth Rate (CAGR)
11.2.4.4. Regional Bifurcation
11.2.4.4.1. North America
11.2.4.4.1.1.
Market Forecast, 2021 - 2029
11.2.4.4.2. Europe
11.2.4.4.2.1.
Market Forecast, 2021 - 2029
11.2.4.4.3. Asia Pacific
11.2.4.4.3.1.
Market Forecast, 2021 - 2029
11.2.4.4.4. Middle East and Africa
11.2.4.4.4.1.
Market Forecast, 2021 - 2029
11.2.4.4.5. Latin America
11.2.4.4.5.1.
Market Forecast, 2021 - 2029
11.3. Key
Segment for Channeling Investments
11.3.1. By End
Use
12. North America Whole Genome Sequencing (WGS) Market Analysis
and Forecasts, 2021 - 2029
12.1. Overview
12.1.1. North
America Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
12.2. North
America Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
Procedures
12.2.1. Large
Whole-Genome Sequencing
12.2.2. Small Genome Sequencing
12.2.3. Phased
Sequencing
12.2.4. Human
Whole-Genome Sequencing
12.2.5. De Novo
Sequencing
12.3. North
America Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
Genome Type
12.3.1. Human
12.3.2. Plant
12.3.3. Animal
12.3.4. Microorganism
12.3.5. Virus
12.3.6. Others
12.4. North
America Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
Application
12.4.1. Food
Safety Management
12.4.2. Identification
of genetic diseases
12.4.3. Drug
Trials and Pharmacogenomics
12.4.4. Rare Disease Diagnosis
12.4.5. Others
12.5. North America
Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By End Use
12.5.1. Hospitals
and Clinics
12.5.2. Academic
Institutions and Research Institutions
12.5.3. Pharmaceutical and Biotechnology Companies
12.5.4. Others
12.6. North
America Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
Country
12.6.1. U.S
12.6.1.1. U.S Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and
Forecasts, By Procedures
12.6.1.1.1. Large Whole-Genome Sequencing
12.6.1.1.2. Small Genome Sequencing
12.6.1.1.3. Phased Sequencing
12.6.1.1.4. Human Whole-Genome Sequencing
12.6.1.1.5. De Novo Sequencing
12.6.1.2. U.S Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and
Forecasts, By Genome Type
12.6.1.2.1. Human
12.6.1.2.2. Plant
12.6.1.2.3. Animal
12.6.1.2.4. Microorganism
12.6.1.2.5. Virus
12.6.1.2.6. Others
12.6.1.3. U.S Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.1.3.1. Food Safety Management
12.6.1.3.2. Identification of genetic diseases
12.6.1.3.3. Drug Trials and Pharmacogenomics
12.6.1.3.4. Rare Disease Diagnosis
12.6.1.3.5. Others
12.6.1.4. U.S Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and
Forecasts, By End Use
12.6.1.4.1. Hospitals and Clinics
12.6.1.4.2. Academic Institutions and Research Institutions
12.6.1.4.3. Pharmaceutical and
Biotechnology Companies
12.6.1.4.4. Others
12.6.2. Canada
12.6.2.1. Canada Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Procedures
12.6.2.1.1. Large Whole-Genome Sequencing
12.6.2.1.2. Small Genome Sequencing
12.6.2.1.3. Phased Sequencing
12.6.2.1.4. Human Whole-Genome Sequencing
12.6.2.1.5. De Novo Sequencing
12.6.2.2. Canada Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Genome Type
12.6.2.2.1. Human
12.6.2.2.2. Plant
12.6.2.2.3. Animal
12.6.2.2.4. Microorganism
12.6.2.2.5. Virus
12.6.2.2.6. Others
12.6.2.3. Canada Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Application
12.6.2.3.1. Food Safety Management
12.6.2.3.2. Identification of genetic diseases
12.6.2.3.3. Drug Trials and Pharmacogenomics
12.6.2.3.4. Rare Disease Diagnosis
12.6.2.3.5. Others
12.6.2.4. Canada Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By End Use
12.6.2.4.1. Hospitals and Clinics
12.6.2.4.2. Academic Institutions and Research Institutions
12.6.2.4.3. Pharmaceutical and
Biotechnology Companies
12.6.2.4.4. Others
12.6.3. Mexico
12.6.3.1. Mexico Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Procedures
12.6.3.1.1. Large Whole-Genome Sequencing
12.6.3.1.2. Small Genome Sequencing
12.6.3.1.3. Phased Sequencing
12.6.3.1.4. Human Whole-Genome Sequencing
12.6.3.1.5. De Novo Sequencing
12.6.3.2. Mexico Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Genome Type
12.6.3.2.1. Human
12.6.3.2.2. Plant
12.6.3.2.3. Animal
12.6.3.2.4. Microorganism
12.6.3.2.5. Virus
12.6.3.2.6. Others
12.6.3.3. Mexico Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Application
12.6.3.3.1. Food Safety Management
12.6.3.3.2. Identification of genetic diseases
12.6.3.3.3. Drug Trials and Pharmacogenomics
12.6.3.3.4. Rare Disease Diagnosis
12.6.3.3.5. Others
12.6.3.4. Mexico Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By End Use
12.6.3.4.1. Hospitals and Clinics
12.6.3.4.2. Academic Institutions and Research Institutions
12.6.3.4.3. Pharmaceutical and
Biotechnology Companies
12.6.3.4.4. Others
12.6.4. Rest of
North America
12.6.4.1. Rest of North America Whole Genome Sequencing (WGS) Market
Revenue (US$ Mn) and Forecasts, By Procedures
12.6.4.1.1. Large Whole-Genome Sequencing
12.6.4.1.2. Small Genome Sequencing
12.6.4.1.3. Phased Sequencing
12.6.4.1.4. Human Whole-Genome Sequencing
12.6.4.1.5. De Novo Sequencing
12.6.4.2. Rest of North America Whole Genome Sequencing (WGS) Market
Revenue (US$ Mn) and Forecasts, By Genome Type
12.6.4.2.1. Human
12.6.4.2.2. Plant
12.6.4.2.3. Animal
12.6.4.2.4. Microorganism
12.6.4.2.5. Virus
12.6.4.2.6. Others
12.6.4.3. Rest of North America Whole Genome Sequencing (WGS) Market
Revenue (US$ Mn) and Forecasts, By Application
12.6.4.3.1. Food Safety Management
12.6.4.3.2. Identification of genetic diseases
12.6.4.3.3. Drug Trials and Pharmacogenomics
12.6.4.3.4. Rare Disease Diagnosis
12.6.4.3.5. Others
12.6.4.4. Rest of North America Whole Genome Sequencing (WGS) Market
Revenue (US$ Mn) and Forecasts, By End Use
12.6.4.4.1. Hospitals and Clinics
12.6.4.4.2. Academic Institutions and Research Institutions
12.6.4.4.3. Pharmaceutical and
Biotechnology Companies
12.6.4.4.4. Others
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By
Procedures
12.7.3. By
Genome Type
12.7.4. By
Application
12.7.5. By End
Use
13. Europe Whole Genome Sequencing (WGS) Market Analysis and
Forecasts, 2021 - 2029
13.1. Overview
13.1.1. Europe
Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
13.2. Europe
Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
Procedures
13.2.1. Large Whole-Genome
Sequencing
13.2.2. Small Genome Sequencing
13.2.3. Phased
Sequencing
13.2.4. Human
Whole-Genome Sequencing
13.2.5. De Novo
Sequencing
13.3. Europe
Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By Genome
Type
13.3.1. Human
13.3.2. Plant
13.3.3. Animal
13.3.4. Microorganism
13.3.5. Virus
13.3.6. Others
13.4. Europe
Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
Application
13.4.1. Food
Safety Management
13.4.2. Identification
of genetic diseases
13.4.3. Drug
Trials and Pharmacogenomics
13.4.4. Rare Disease Diagnosis
13.4.5. Others
13.5. Europe
Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By End Use
13.5.1. Hospitals
and Clinics
13.5.2. Academic
Institutions and Research Institutions
13.5.3. Pharmaceutical and Biotechnology Companies
13.5.4. Others
13.6. Europe
Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Procedures
13.6.1.1.1. Large Whole-Genome Sequencing
13.6.1.1.2. Small Genome Sequencing
13.6.1.1.3. Phased Sequencing
13.6.1.1.4. Human Whole-Genome Sequencing
13.6.1.1.5. De Novo Sequencing
13.6.1.2. France Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Genome Type
13.6.1.2.1. Human
13.6.1.2.2. Plant
13.6.1.2.3. Animal
13.6.1.2.4. Microorganism
13.6.1.2.5. Virus
13.6.1.2.6. Others
13.6.1.3. France Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.1.3.1. Food Safety Management
13.6.1.3.2. Identification of genetic diseases
13.6.1.3.3. Drug Trials and Pharmacogenomics
13.6.1.3.4. Rare Disease Diagnosis
13.6.1.3.5. Others
13.6.1.4. France Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By End Use
13.6.1.4.1. Hospitals and Clinics
13.6.1.4.2. Academic Institutions and Research Institutions
13.6.1.4.3. Pharmaceutical and
Biotechnology Companies
13.6.1.4.4. Others
13.6.2. The UK
13.6.2.1. The UK Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Procedures
13.6.2.1.1. Large Whole-Genome Sequencing
13.6.2.1.2. Small Genome Sequencing
13.6.2.1.3. Phased Sequencing
13.6.2.1.4. Human Whole-Genome Sequencing
13.6.2.1.5. De Novo Sequencing
13.6.2.2. The UK Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Genome Type
13.6.2.2.1. Human
13.6.2.2.2. Plant
13.6.2.2.3. Animal
13.6.2.2.4. Microorganism
13.6.2.2.5. Virus
13.6.2.2.6. Others
13.6.2.3. The UK Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.2.3.1. Food Safety Management
13.6.2.3.2. Identification of genetic diseases
13.6.2.3.3. Drug Trials and Pharmacogenomics
13.6.2.3.4. Rare Disease Diagnosis
13.6.2.3.5. Others
13.6.2.4. The UK Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By End Use
13.6.2.4.1. Hospitals and Clinics
13.6.2.4.2. Academic Institutions and Research Institutions
13.6.2.4.3. Pharmaceutical and Biotechnology
Companies
13.6.2.4.4. Others
13.6.3. Spain
13.6.3.1. Spain Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Procedures
13.6.3.1.1. Large Whole-Genome Sequencing
13.6.3.1.2. Small Genome Sequencing
13.6.3.1.3. Phased Sequencing
13.6.3.1.4. Human Whole-Genome Sequencing
13.6.3.1.5. De Novo Sequencing
13.6.3.2. Spain Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Genome Type
13.6.3.2.1. Human
13.6.3.2.2. Plant
13.6.3.2.3. Animal
13.6.3.2.4. Microorganism
13.6.3.2.5. Virus
13.6.3.2.6. Others
13.6.3.3. Spain Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.3.3.1. Food Safety Management
13.6.3.3.2. Identification of genetic diseases
13.6.3.3.3. Drug Trials and Pharmacogenomics
13.6.3.3.4. Rare Disease Diagnosis
13.6.3.3.5. Others
13.6.3.4. Spain Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By End Use
13.6.3.4.1. Hospitals and Clinics
13.6.3.4.2. Academic Institutions and Research Institutions
13.6.3.4.3. Pharmaceutical and
Biotechnology Companies
13.6.3.4.4. Others
13.6.4. Germany
13.6.4.1. Germany Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Procedures
13.6.4.1.1. Large Whole-Genome Sequencing
13.6.4.1.2. Small Genome Sequencing
13.6.4.1.3. Phased Sequencing
13.6.4.1.4. Human Whole-Genome Sequencing
13.6.4.1.5. De Novo Sequencing
13.6.4.2. Germany Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Genome Type
13.6.4.2.1. Human
13.6.4.2.2. Plant
13.6.4.2.3. Animal
13.6.4.2.4. Microorganism
13.6.4.2.5. Virus
13.6.4.2.6. Others
13.6.4.3. Germany Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.4.3.1. Food Safety Management
13.6.4.3.2. Identification of genetic diseases
13.6.4.3.3. Drug Trials and Pharmacogenomics
13.6.4.3.4. Rare Disease Diagnosis
13.6.4.3.5. Others
13.6.4.4. Germany Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By End Use
13.6.4.4.1. Hospitals and Clinics
13.6.4.4.2. Academic Institutions and Research Institutions
13.6.4.4.3. Pharmaceutical and
Biotechnology Companies
13.6.4.4.4. Others
13.6.5. Italy
13.6.5.1. Italy Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Procedures
13.6.5.1.1. Large Whole-Genome Sequencing
13.6.5.1.2. Small Genome Sequencing
13.6.5.1.3. Phased Sequencing
13.6.5.1.4. Human Whole-Genome Sequencing
13.6.5.1.5. De Novo Sequencing
13.6.5.2. Italy Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Genome Type
13.6.5.2.1. Human
13.6.5.2.2. Plant
13.6.5.2.3. Animal
13.6.5.2.4. Microorganism
13.6.5.2.5. Virus
13.6.5.2.6. Others
13.6.5.3. Italy Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.5.3.1. Food Safety Management
13.6.5.3.2. Identification of genetic diseases
13.6.5.3.3. Drug Trials and Pharmacogenomics
13.6.5.3.4. Rare Disease Diagnosis
13.6.5.3.5. Others
13.6.5.4. Italy Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By End Use
13.6.5.4.1. Hospitals and Clinics
13.6.5.4.2. Academic Institutions and Research Institutions
13.6.5.4.3. Pharmaceutical and
Biotechnology Companies
13.6.5.4.4. Others
13.6.6. Nordic
Countries
13.6.6.1. Nordic Countries Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By Procedures
13.6.6.1.1. Large Whole-Genome Sequencing
13.6.6.1.2. Small Genome Sequencing
13.6.6.1.3. Phased Sequencing
13.6.6.1.4. Human Whole-Genome Sequencing
13.6.6.1.5. De Novo Sequencing
13.6.6.2. Nordic Countries Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By Genome Type
13.6.6.2.1. Human
13.6.6.2.2. Plant
13.6.6.2.3. Animal
13.6.6.2.4. Microorganism
13.6.6.2.5. Virus
13.6.6.2.6. Others
13.6.6.3. Nordic Countries Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Application
13.6.6.3.1. Food Safety Management
13.6.6.3.2. Identification of genetic diseases
13.6.6.3.3. Drug Trials and Pharmacogenomics
13.6.6.3.4. Rare Disease Diagnosis
13.6.6.3.5. Others
13.6.6.4. Nordic Countries Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By End Use
13.6.6.4.1. Hospitals and Clinics
13.6.6.4.2. Academic Institutions and Research Institutions
13.6.6.4.3. Pharmaceutical and
Biotechnology Companies
13.6.6.4.4. Others
13.6.6.5. Nordic Countries Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux Union Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By Procedures
13.6.7.1.1. Large Whole-Genome Sequencing
13.6.7.1.2. Small Genome Sequencing
13.6.7.1.3. Phased Sequencing
13.6.7.1.4. Human Whole-Genome Sequencing
13.6.7.1.5. De Novo Sequencing
13.6.7.2. Benelux Union Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By Genome Type
13.6.7.2.1. Human
13.6.7.2.2. Plant
13.6.7.2.3. Animal
13.6.7.2.4. Microorganism
13.6.7.2.5. Virus
13.6.7.2.6. Others
13.6.7.3. Benelux Union Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.7.3.1. Food Safety Management
13.6.7.3.2. Identification of genetic diseases
13.6.7.3.3. Drug Trials and Pharmacogenomics
13.6.7.3.4. Rare Disease Diagnosis
13.6.7.3.5. Others
13.6.7.4. Benelux Union Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By End Use
13.6.7.4.1. Hospitals and Clinics
13.6.7.4.2. Academic Institutions and Research Institutions
13.6.7.4.3. Pharmaceutical and
Biotechnology Companies
13.6.7.4.4. Others
13.6.7.5. Benelux Union Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest of Europe Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By Procedures
13.6.8.1.1. Large Whole-Genome Sequencing
13.6.8.1.2. Small Genome Sequencing
13.6.8.1.3. Phased Sequencing
13.6.8.1.4. Human Whole-Genome Sequencing
13.6.8.1.5. De Novo Sequencing
13.6.8.2. Rest of Europe Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By Genome Type
13.6.8.2.1. Human
13.6.8.2.2. Plant
13.6.8.2.3. Animal
13.6.8.2.4. Microorganism
13.6.8.2.5. Virus
13.6.8.2.6. Others
13.6.8.3. Rest of Europe Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.8.3.1. Food Safety Management
13.6.8.3.2. Identification of genetic diseases
13.6.8.3.3. Drug Trials and Pharmacogenomics
13.6.8.3.4. Rare Disease Diagnosis
13.6.8.3.5. Others
13.6.8.4. Rest of Europe Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By End Use
13.6.8.4.1. Hospitals and Clinics
13.6.8.4.2. Academic Institutions and Research Institutions
13.6.8.4.3. Pharmaceutical and
Biotechnology Companies
13.6.8.4.4. Others
13.7. Key Segment
for Channeling Investments
13.7.1. By
Country
13.7.2. By
Procedures
13.7.3. By
Genome Type
13.7.4. By
Application
13.7.5. By End
Use
14. Asia Pacific Whole Genome Sequencing (WGS) Market Analysis
and Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Asia
Pacific Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
14.2. Asia
Pacific Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
Procedures
14.2.1. Large
Whole-Genome Sequencing
14.2.2. Small Genome Sequencing
14.2.3. Phased
Sequencing
14.2.4. Human
Whole-Genome Sequencing
14.2.5. De Novo
Sequencing
14.3. Asia
Pacific Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
Genome Type
14.3.1. Human
14.3.2. Plant
14.3.3. Animal
14.3.4. Microorganism
14.3.5. Virus
14.3.6. Others
14.4. Asia
Pacific Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
Application
14.4.1. Food
Safety Management
14.4.2. Identification
of genetic diseases
14.4.3. Drug
Trials and Pharmacogenomics
14.4.4. Rare Disease Diagnosis
14.4.5. Others
14.5. Asia
Pacific Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
End Use
14.5.1. Hospitals
and Clinics
14.5.2. Academic
Institutions and Research Institutions
14.5.3. Pharmaceutical and Biotechnology Companies
14.5.4. Others
14.6. Asia
Pacific Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.1. China
14.6.1.1. China Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Procedures
14.6.1.1.1. Large Whole-Genome Sequencing
14.6.1.1.2. Small Genome Sequencing
14.6.1.1.3. Phased Sequencing
14.6.1.1.4. Human Whole-Genome Sequencing
14.6.1.1.5. De Novo Sequencing
14.6.1.2. China Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Genome Type
14.6.1.2.1. Human
14.6.1.2.2. Plant
14.6.1.2.3. Animal
14.6.1.2.4. Microorganism
14.6.1.2.5. Virus
14.6.1.2.6. Others
14.6.1.3. China Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.1.3.1. Food Safety Management
14.6.1.3.2. Identification of genetic diseases
14.6.1.3.3. Drug Trials and Pharmacogenomics
14.6.1.3.4. Rare Disease Diagnosis
14.6.1.3.5. Others
14.6.1.4. China Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By End Use
14.6.1.4.1. Hospitals and Clinics
14.6.1.4.2. Academic Institutions and Research Institutions
14.6.1.4.3. Pharmaceutical and
Biotechnology Companies
14.6.1.4.4. Others
14.6.2. Japan
14.6.2.1. Japan Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Procedures
14.6.2.1.1. Large Whole-Genome Sequencing
14.6.2.1.2. Small Genome Sequencing
14.6.2.1.3. Phased Sequencing
14.6.2.1.4. Human Whole-Genome Sequencing
14.6.2.1.5. De Novo Sequencing
14.6.2.2. Japan Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Genome Type
14.6.2.2.1. Human
14.6.2.2.2. Plant
14.6.2.2.3. Animal
14.6.2.2.4. Microorganism
14.6.2.2.5. Virus
14.6.2.2.6. Others
14.6.2.3. Japan Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.2.3.1. Food Safety Management
14.6.2.3.2. Identification of genetic diseases
14.6.2.3.3. Drug Trials and Pharmacogenomics
14.6.2.3.4. Rare Disease Diagnosis
14.6.2.3.5. Others
14.6.2.4. Japan Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By End Use
14.6.2.4.1. Hospitals and Clinics
14.6.2.4.2. Academic Institutions and Research Institutions
14.6.2.4.3. Pharmaceutical and
Biotechnology Companies
14.6.2.4.4. Others
14.6.3. India
14.6.3.1. India Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Procedures
14.6.3.1.1. Large Whole-Genome Sequencing
14.6.3.1.2. Small Genome Sequencing
14.6.3.1.3. Phased Sequencing
14.6.3.1.4. Human Whole-Genome Sequencing
14.6.3.1.5. De Novo Sequencing
14.6.3.2. India Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Genome Type
14.6.3.2.1. Human
14.6.3.2.2. Plant
14.6.3.2.3. Animal
14.6.3.2.4. Microorganism
14.6.3.2.5. Virus
14.6.3.2.6. Others
14.6.3.3. India Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.3.3.1. Food Safety Management
14.6.3.3.2. Identification of genetic diseases
14.6.3.3.3. Drug Trials and Pharmacogenomics
14.6.3.3.4. Rare Disease Diagnosis
14.6.3.3.5. Others
14.6.3.4. India Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By End Use
14.6.3.4.1. Hospitals and Clinics
14.6.3.4.2. Academic Institutions and Research Institutions
14.6.3.4.3. Pharmaceutical and
Biotechnology Companies
14.6.3.4.4. Others
14.6.4. New
Zealand
14.6.4.1. New Zealand Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Procedures
14.6.4.1.1. Large Whole-Genome Sequencing
14.6.4.1.2. Small Genome Sequencing
14.6.4.1.3. Phased Sequencing
14.6.4.1.4. Human Whole-Genome Sequencing
14.6.4.1.5. De Novo Sequencing
14.6.4.2. New Zealand Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Genome Type
14.6.4.2.1. Human
14.6.4.2.2. Plant
14.6.4.2.3. Animal
14.6.4.2.4. Microorganism
14.6.4.2.5. Virus
14.6.4.2.6. Others
14.6.4.3. New Zealand Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Application
14.6.4.3.1. Food Safety Management
14.6.4.3.2. Identification of genetic diseases
14.6.4.3.3. Drug Trials and Pharmacogenomics
14.6.4.3.4. Rare Disease Diagnosis
14.6.4.3.5. Others
14.6.4.4. New Zealand Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By End Use
14.6.4.4.1. Hospitals and Clinics
14.6.4.4.2. Academic Institutions and Research Institutions
14.6.4.4.3. Pharmaceutical and
Biotechnology Companies
14.6.4.4.4. Others
14.6.5. Australia
14.6.5.1. Australia Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Procedures
14.6.5.1.1. Large Whole-Genome Sequencing
14.6.5.1.2. Small Genome Sequencing
14.6.5.1.3. Phased Sequencing
14.6.5.1.4. Human Whole-Genome Sequencing
14.6.5.1.5. De Novo Sequencing
14.6.5.2. Australia Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Genome Type
14.6.5.2.1. Human
14.6.5.2.2. Plant
14.6.5.2.3. Animal
14.6.5.2.4. Microorganism
14.6.5.2.5. Virus
14.6.5.2.6. Others
14.6.5.3. Australia Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Application
14.6.5.3.1. Food Safety Management
14.6.5.3.2. Identification of genetic diseases
14.6.5.3.3. Drug Trials and Pharmacogenomics
14.6.5.3.4. Rare Disease Diagnosis
14.6.5.3.5. Others
14.6.5.4. Australia Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By End Use
14.6.5.4.1. Hospitals and Clinics
14.6.5.4.2. Academic Institutions and Research Institutions
14.6.5.4.3. Pharmaceutical and
Biotechnology Companies
14.6.5.4.4. Others
14.6.6. South
Korea
14.6.6.1. South Korea Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Procedures
14.6.6.1.1. Large Whole-Genome Sequencing
14.6.6.1.2. Small Genome Sequencing
14.6.6.1.3. Phased Sequencing
14.6.6.1.4. Human Whole-Genome Sequencing
14.6.6.1.5. De Novo Sequencing
14.6.6.2. South Korea Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Genome Type
14.6.6.2.1. Human
14.6.6.2.2. Plant
14.6.6.2.3. Animal
14.6.6.2.4. Microorganism
14.6.6.2.5. Virus
14.6.6.2.6. Others
14.6.6.3. South Korea Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Application
14.6.6.3.1. Food Safety Management
14.6.6.3.2. Identification of genetic diseases
14.6.6.3.3. Drug Trials and Pharmacogenomics
14.6.6.3.4. Rare Disease Diagnosis
14.6.6.3.5. Others
14.6.6.4. South Korea Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By End Use
14.6.6.4.1. Hospitals and Clinics
14.6.6.4.2. Academic Institutions and Research Institutions
14.6.6.4.3. Pharmaceutical and
Biotechnology Companies
14.6.6.4.4. Others
14.6.7. Southeast
Asia
14.6.7.1. Southeast Asia Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By Procedures
14.6.7.1.1. Large Whole-Genome Sequencing
14.6.7.1.2. Small Genome Sequencing
14.6.7.1.3. Phased Sequencing
14.6.7.1.4. Human Whole-Genome Sequencing
14.6.7.1.5. De Novo Sequencing
14.6.7.2. Southeast Asia Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By Genome Type
14.6.7.2.1. Human
14.6.7.2.2. Plant
14.6.7.2.3. Animal
14.6.7.2.4. Microorganism
14.6.7.2.5. Virus
14.6.7.2.6. Others
14.6.7.3. Southeast Asia Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By Application
14.6.7.3.1. Food Safety Management
14.6.7.3.2. Identification of genetic diseases
14.6.7.3.3. Drug Trials and Pharmacogenomics
14.6.7.3.4. Rare Disease Diagnosis
14.6.7.3.5. Others
14.6.7.4. Southeast Asia Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By End Use
14.6.7.4.1. Hospitals and Clinics
14.6.7.4.2. Academic Institutions and Research Institutions
14.6.7.4.3. Pharmaceutical and
Biotechnology Companies
14.6.7.4.4. Others
14.6.7.5. Southeast Asia Whole Genome Sequencing (WGS) Market Revenue
(US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest of Asia Pacific Whole Genome Sequencing (WGS) Market
Revenue (US$ Mn) and Forecasts, By Procedures
14.6.8.1.1. Large Whole-Genome Sequencing
14.6.8.1.2. Small Genome Sequencing
14.6.8.1.3. Phased Sequencing
14.6.8.1.4. Human Whole-Genome Sequencing
14.6.8.1.5. De Novo Sequencing
14.6.8.2. Rest of Asia Pacific Whole Genome Sequencing (WGS) Market
Revenue (US$ Mn) and Forecasts, By Genome Type
14.6.8.2.1. Human
14.6.8.2.2. Plant
14.6.8.2.3. Animal
14.6.8.2.4. Microorganism
14.6.8.2.5. Virus
14.6.8.2.6. Others
14.6.8.3. Rest of Asia Pacific Whole Genome Sequencing (WGS) Market
Revenue (US$ Mn) and Forecasts, By Application
14.6.8.3.1. Food Safety Management
14.6.8.3.2. Identification of genetic diseases
14.6.8.3.3. Drug Trials and Pharmacogenomics
14.6.8.3.4. Rare Disease Diagnosis
14.6.8.3.5. Others
14.6.8.4. Rest of Asia Pacific Whole Genome Sequencing (WGS) Market
Revenue (US$ Mn) and Forecasts, By End Use
14.6.8.4.1. Hospitals and Clinics
14.6.8.4.2. Academic Institutions and Research Institutions
14.6.8.4.3. Pharmaceutical and
Biotechnology Companies
14.6.8.4.4. Others
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By
Procedures
14.7.3. By
Genome Type
14.7.4. By
Application
14.7.5. By End
Use
15. Middle East and Africa Whole Genome Sequencing (WGS) Market
Analysis and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Middle
East and Africa Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
15.2. Middle
East and Africa Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and
Forecasts, By Procedures
15.2.1. Large
Whole-Genome Sequencing
15.2.2. Small Genome Sequencing
15.2.3. Phased
Sequencing
15.2.4. Human
Whole-Genome Sequencing
15.2.5. De Novo
Sequencing
15.3. Middle
East and Africa Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and
Forecasts, By Genome Type
15.3.1. Human
15.3.2. Plant
15.3.3. Animal
15.3.4. Microorganism
15.3.5. Virus
15.3.6. Others
15.4. Middle
East and Africa Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and
Forecasts, By Application
15.4.1. Food
Safety Management
15.4.2. Identification
of genetic diseases
15.4.3. Drug
Trials and Pharmacogenomics
15.4.4. Rare Disease Diagnosis
15.4.5. Others
15.5. Middle
East and Africa Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and
Forecasts, By End Use
15.5.1. Hospitals
and Clinics
15.5.2. Academic
Institutions and Research Institutions
15.5.3. Pharmaceutical and Biotechnology Companies
15.5.4. Others
15.6. Middle
East and Africa Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and
Forecasts, By Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi Arabia Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Procedures
15.6.1.1.1. Large Whole-Genome Sequencing
15.6.1.1.2. Small Genome Sequencing
15.6.1.1.3. Phased Sequencing
15.6.1.1.4. Human Whole-Genome Sequencing
15.6.1.1.5. De Novo Sequencing
15.6.1.2. Saudi Arabia Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Genome Type
15.6.1.2.1. Human
15.6.1.2.2. Plant
15.6.1.2.3. Animal
15.6.1.2.4. Microorganism
15.6.1.2.5. Virus
15.6.1.2.6. Others
15.6.1.3. Saudi Arabia Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Application
15.6.1.3.1. Food Safety Management
15.6.1.3.2. Identification of genetic diseases
15.6.1.3.3. Drug Trials and Pharmacogenomics
15.6.1.3.4. Rare Disease Diagnosis
15.6.1.3.5. Others
15.6.1.4. Saudi Arabia Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By End Use
15.6.1.4.1. Hospitals and Clinics
15.6.1.4.2. Academic Institutions and Research Institutions
15.6.1.4.3. Pharmaceutical and
Biotechnology Companies
15.6.1.4.4. Others
15.6.2. UAE
15.6.2.1. UAE Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and
Forecasts, By Procedures
15.6.2.1.1. Large Whole-Genome Sequencing
15.6.2.1.2. Small Genome Sequencing
15.6.2.1.3. Phased Sequencing
15.6.2.1.4. Human Whole-Genome Sequencing
15.6.2.1.5. De Novo Sequencing
15.6.2.2. UAE Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and
Forecasts, By Genome Type
15.6.2.2.1. Human
15.6.2.2.2. Plant
15.6.2.2.3. Animal
15.6.2.2.4. Microorganism
15.6.2.2.5. Virus
15.6.2.2.6. Others
15.6.2.3. UAE Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.2.3.1. Food Safety Management
15.6.2.3.2. Identification of genetic diseases
15.6.2.3.3. Drug Trials and Pharmacogenomics
15.6.2.3.4. Rare Disease Diagnosis
15.6.2.3.5. Others
15.6.2.4. UAE Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and
Forecasts, By End Use
15.6.2.4.1. Hospitals and Clinics
15.6.2.4.2. Academic Institutions and Research Institutions
15.6.2.4.3. Pharmaceutical and
Biotechnology Companies
15.6.2.4.4. Others
15.6.3. Egypt
15.6.3.1. Egypt Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Procedures
15.6.3.1.1. Large Whole-Genome Sequencing
15.6.3.1.2. Small Genome Sequencing
15.6.3.1.3. Phased Sequencing
15.6.3.1.4. Human Whole-Genome Sequencing
15.6.3.1.5. De Novo Sequencing
15.6.3.2. Egypt Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Genome Type
15.6.3.2.1. Human
15.6.3.2.2. Plant
15.6.3.2.3. Animal
15.6.3.2.4. Microorganism
15.6.3.2.5. Virus
15.6.3.2.6. Others
15.6.3.3. Egypt Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Application
15.6.3.3.1. Food Safety Management
15.6.3.3.2. Identification of genetic diseases
15.6.3.3.3. Drug Trials and Pharmacogenomics
15.6.3.3.4. Rare Disease Diagnosis
15.6.3.3.5. Others
15.6.3.4. Egypt Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By End Use
15.6.3.4.1. Hospitals and Clinics
15.6.3.4.2. Academic Institutions and Research Institutions
15.6.3.4.3. Pharmaceutical and
Biotechnology Companies
15.6.3.4.4. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Procedures
15.6.4.1.1. Large Whole-Genome Sequencing
15.6.4.1.2. Small Genome Sequencing
15.6.4.1.3. Phased Sequencing
15.6.4.1.4. Human Whole-Genome Sequencing
15.6.4.1.5. De Novo Sequencing
15.6.4.2. Kuwait Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Genome Type
15.6.4.2.1. Human
15.6.4.2.2. Plant
15.6.4.2.3. Animal
15.6.4.2.4. Microorganism
15.6.4.2.5. Virus
15.6.4.2.6. Others
15.6.4.3. Kuwait Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Application
15.6.4.3.1. Food Safety Management
15.6.4.3.2. Identification of genetic diseases
15.6.4.3.3. Drug Trials and Pharmacogenomics
15.6.4.3.4. Rare Disease Diagnosis
15.6.4.3.5. Others
15.6.4.4. Kuwait Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By End Use
15.6.4.4.1. Hospitals and Clinics
15.6.4.4.2. Academic Institutions and Research Institutions
15.6.4.4.3. Pharmaceutical and
Biotechnology Companies
15.6.4.4.4. Others
15.6.5. South
Africa
15.6.5.1. South Africa Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Procedures
15.6.5.1.1. Large Whole-Genome Sequencing
15.6.5.1.2. Small Genome Sequencing
15.6.5.1.3. Phased Sequencing
15.6.5.1.4. Human Whole-Genome Sequencing
15.6.5.1.5. De Novo Sequencing
15.6.5.2. South Africa Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Genome Type
15.6.5.2.1. Human
15.6.5.2.2. Plant
15.6.5.2.3. Animal
15.6.5.2.4. Microorganism
15.6.5.2.5. Virus
15.6.5.2.6. Others
15.6.5.3. South Africa Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Application
15.6.5.3.1. Food Safety Management
15.6.5.3.2. Identification of genetic diseases
15.6.5.3.3. Drug Trials and Pharmacogenomics
15.6.5.3.4. Rare Disease Diagnosis
15.6.5.3.5. Others
15.6.5.4. South Africa Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By End Use
15.6.5.4.1. Hospitals and Clinics
15.6.5.4.2. Academic Institutions and Research Institutions
15.6.5.4.3. Pharmaceutical and
Biotechnology Companies
15.6.5.4.4. Others
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Whole Genome Sequencing (WGS)
Market Revenue (US$ Mn) and Forecasts, By Procedures
15.6.6.1.1. Large Whole-Genome Sequencing
15.6.6.1.2. Small Genome Sequencing
15.6.6.1.3. Phased Sequencing
15.6.6.1.4. Human Whole-Genome Sequencing
15.6.6.1.5. De Novo Sequencing
15.6.6.2. Rest of Middle East & Africa Whole Genome Sequencing (WGS)
Market Revenue (US$ Mn) and Forecasts, By Genome Type
15.6.6.2.1. Human
15.6.6.2.2. Plant
15.6.6.2.3. Animal
15.6.6.2.4. Microorganism
15.6.6.2.5. Virus
15.6.6.2.6. Others
15.6.6.3. Rest of Middle East & Africa Whole Genome Sequencing (WGS)
Market Revenue (US$ Mn) and Forecasts, By Application
15.6.6.3.1. Food Safety Management
15.6.6.3.2. Identification of genetic diseases
15.6.6.3.3. Drug Trials and Pharmacogenomics
15.6.6.3.4. Rare Disease Diagnosis
15.6.6.3.5. Others
15.6.6.4. Rest of Middle East & Africa Whole Genome Sequencing (WGS)
Market Revenue (US$ Mn) and Forecasts, By End Use
15.6.6.4.1. Hospitals and Clinics
15.6.6.4.2. Academic Institutions and Research Institutions
15.6.6.4.3. Pharmaceutical and
Biotechnology Companies
15.6.6.4.4. Others
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By
Procedures
15.7.3. By
Genome Type
15.7.4. By
Application
15.7.5. By End
Use
16. Latin America Whole Genome Sequencing (WGS) Market Analysis
and Forecasts, 2021 - 2029
16.1. Overview
16.1.1. Latin
America Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
16.2. Latin
America Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
Procedures
16.2.1. Large
Whole-Genome Sequencing
16.2.2. Small Genome Sequencing
16.2.3. Phased
Sequencing
16.2.4. Human
Whole-Genome Sequencing
16.2.5. De Novo
Sequencing
16.3. Latin
America Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
Genome Type
16.3.1. Human
16.3.2. Plant
16.3.3. Animal
16.3.4. Microorganism
16.3.5. Virus
16.3.6. Others
16.4. Latin
America Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
Application
16.4.1. Food
Safety Management
16.4.2. Identification
of genetic diseases
16.4.3. Drug
Trials and Pharmacogenomics
16.4.4. Rare Disease Diagnosis
16.4.5. Others
16.5. Latin
America Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
End Use
16.5.1. Hospitals
and Clinics
16.5.2. Academic
Institutions and Research Institutions
16.5.3. Pharmaceutical and Biotechnology Companies
16.5.4. Others
16.6. Latin
America Whole Genome Sequencing (WGS) Market Revenue (US$ Mn) and Forecasts, By
Country
16.6.1. Brazil
16.6.1.1. Brazil Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Procedures
16.6.1.1.1. Large Whole-Genome Sequencing
16.6.1.1.2. Small Genome Sequencing
16.6.1.1.3. Phased Sequencing
16.6.1.1.4. Human Whole-Genome Sequencing
16.6.1.1.5. De Novo Sequencing
16.6.1.2. Brazil Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Genome Type
16.6.1.2.1. Human
16.6.1.2.2. Plant
16.6.1.2.3. Animal
16.6.1.2.4. Microorganism
16.6.1.2.5. Virus
16.6.1.2.6. Others
16.6.1.3. Brazil Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By Application
16.6.1.3.1. Food Safety Management
16.6.1.3.2. Identification of genetic diseases
16.6.1.3.3. Drug Trials and Pharmacogenomics
16.6.1.3.4. Rare Disease Diagnosis
16.6.1.3.5. Others
16.6.1.4. Brazil Whole Genome Sequencing (WGS) Market Revenue (US$ Mn)
and Forecasts, By End Use
16.6.1.4.1. Hospitals and Clinics
16.6.1.4.2. Academic Institutions and Research Institutions
16.6.1.4.3. Pharmaceutical and
Biotechnology Companies
16.6.1.4.4. Others
16.6.2. Argentina
16.6.2.1. Argentina Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Procedures
16.6.2.1.1. Large Whole-Genome Sequencing
16.6.2.1.2. Small Genome Sequencing
16.6.2.1.3. Phased Sequencing
16.6.2.1.4. Human Whole-Genome Sequencing
16.6.2.1.5. De Novo Sequencing
16.6.2.2. Argentina Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Genome Type
16.6.2.2.1. Human
16.6.2.2.2. Plant
16.6.2.2.3. Animal
16.6.2.2.4. Microorganism
16.6.2.2.5. Virus
16.6.2.2.6. Others
16.6.2.3. Argentina Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By Application
16.6.2.3.1. Food Safety Management
16.6.2.3.2. Identification of genetic diseases
16.6.2.3.3. Drug Trials and Pharmacogenomics
16.6.2.3.4. Rare Disease Diagnosis
16.6.2.3.5. Others
16.6.2.4. Argentina Whole Genome Sequencing (WGS) Market Revenue (US$
Mn) and Forecasts, By End Use
16.6.2.4.1. Hospitals and Clinics
16.6.2.4.2. Academic Institutions and Research Institutions
16.6.2.4.3. Pharmaceutical and
Biotechnology Companies
16.6.2.4.4. Others
16.6.3. Rest of
Latin America
16.6.3.1. Rest of Latin America Whole Genome Sequencing (WGS) Market
Revenue (US$ Mn) and Forecasts, By Procedures
16.6.3.1.1. Large Whole-Genome Sequencing
16.6.3.1.2. Small Genome Sequencing
16.6.3.1.3. Phased Sequencing
16.6.3.1.4. Human Whole-Genome Sequencing
16.6.3.1.5. De Novo Sequencing
16.6.3.2. Rest of Latin America Whole Genome Sequencing (WGS) Market
Revenue (US$ Mn) and Forecasts, By Genome Type
16.6.3.2.1. Human
16.6.3.2.2. Plant
16.6.3.2.3. Animal
16.6.3.2.4. Microorganism
16.6.3.2.5. Virus
16.6.3.2.6. Others
16.6.3.3. Rest of Latin America Whole Genome Sequencing (WGS) Market
Revenue (US$ Mn) and Forecasts, By Application
16.6.3.3.1. Food Safety Management
16.6.3.3.2. Identification of genetic diseases
16.6.3.3.3. Drug Trials and Pharmacogenomics
16.6.3.3.4. Rare Disease Diagnosis
16.6.3.3.5. Others
16.6.3.4. Rest of Latin America Whole Genome Sequencing (WGS) Market
Revenue (US$ Mn) and Forecasts, By End Use
16.6.3.4.1. Hospitals and Clinics
16.6.3.4.2. Academic Institutions and Research Institutions
16.6.3.4.3. Pharmaceutical and
Biotechnology Companies
16.6.3.4.4. Others
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By
Procedures
16.7.3. By
Genome Type
16.7.4. By
Application
16.7.5. By End
Use
17. Competitive Benchmarking
17.1. Brand
Benchmarking
17.2. Market
Share Analysis, 2022
17.3. Global
Presence and Growth Strategies
17.3.1. Mergers
and Acquisitions
17.3.2. Product
Launches
17.3.3. Investments
Trends
17.3.4. R&D
Initiatives
18. Player Profiles
18.1. 10x
Genomics
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. Agilent Technologies
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business
Strategies
18.3. BGI
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT Analysis
18.3.7. Business
Strategies
18.4. Eurofins Genomics, Inc.
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. GENEWIZ
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business
Strategies
18.6. Illumina, Inc.
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. Macrogen Europe B.V
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business
Strategies
18.8. Oxford Nanopore
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. Qiagen N.V.
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. SIMPLIFY GENOMICS
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT
Analysis
18.10.7. Business
Strategies
18.11. Thermo Fisher Scientific, Inc.
18.11.1. Company
Details
18.11.2. Company
Overview
18.11.3. Product
Offerings
18.11.4. Key
Developments
18.11.5. Financial
Analysis
18.11.6. SWOT
Analysis
18.11.7. Business
Strategies
18.12. Veritas
18.12.1. Company
Details
18.12.2. Company
Overview
18.12.3. Product
Offerings
18.12.4. Key
Developments
18.12.5. Financial
Analysis
18.12.6. SWOT
Analysis
18.12.7. Business
Strategies
18.13. Other
Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
